Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retlirafusp Alfa Combined With Definitive Concurrent Chemoradiotherapy in Local Advanced Unresectable Esophageal Squamous Cell Cancer

NCT07769866 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT07769866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07769866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retlirafusp Alfa Combined With Definitive Concurrent Chemoradiotherapy in Local Advanced Unresectable Esophageal Squamous Cell Cancer
Lead sponsor
RenJi Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
June 30, 2030
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell cancer